Cancer & Oncology Clinical Trials Update: Week 18, 2026
Published May 1, 2026 — 5 trials covered
By Victor Lafforgue, Founder of TrialsAlert. Blog posts are AI-drafted from ClinicalTrials.gov source data and reviewed by the editorial team. See our editorial policy for details.
A Phase III, Open-Label Study of Maintenance Lurbinectedin in Combination With Atezolizumab Compared With Atezolizumab in Participants With Extensive-Stage Small-Cell Lung Cancer
This Phase III trial studied a combination of lurbinectedin and atezolizumab as maintenance treatment for people with extensive-stage small-cell lung cancer. The results, available from multiple countries, suggest this combination could offer a new way to extend survival after initial chemotherapy and immunotherapy. For patients, this means there may soon be an additional option to help control their disease following first treatments.
Induction Pembrolizumab and Chemotherapy Followed by Pembrolizumab Before Chemoradiation and Pembrolizumab Maintenance Compared to Standard Chemoradiation With Pembrolizumab Followed by Pembrolizumab Maintenance in High-Risk Cervical Cancer
This ongoing Phase III trial is testing a treatment plan that starts with pembrolizumab immunotherapy combined with chemotherapy, followed by chemoradiation and ongoing pembrolizumab, for patients with high-risk locally advanced cervical cancer. The goal is to see if this approach improves outcomes compared to the usual treatment of chemoradiation plus pembrolizumab. Patients with advanced cervical cancer in the United States may have access to this potentially more effective treatment through the study.
A Study of Amivantamab and mFOLFOX6 or FOLFIRI Versus Cetuximab and mFOLFOX6 or FOLFIRI as First-line Treatment in Participants With KRAS/NRAS and BRAF Wild-type Unresectable or Metastatic Left-sided Colorectal Cancer
This Phase III trial is evaluating a new antibody drug called amivantamab combined with chemotherapy against the current standard therapy in adults with certain genetic types of advanced colorectal cancer. The study focuses on patients whose tumors do not have KRAS, NRAS, or BRAF mutations. If successful, amivantamab could become a new option that helps patients live longer without their cancer worsening. The trial is recruiting participants in many countries.
A Global Phase III Study of Rilvegostomig or Pembrolizumab Monotherapy for First-Line Treatment of PD-L1-high Metastatic Non-small Cell Lung Cancer
This global Phase III trial compares rilvegostomig to pembrolizumab alone for patients with metastatic non-small cell lung cancer that has high PD-L1 levels. This study may identify a new first treatment option that could improve survival or serve as an alternative to current immunotherapy. With over 800 participants, the trial is accessible to many patients worldwide.
A Study to Evaluate the Benefit of Adding Durvalumab After Chemotherapy, Durvalumab and Surgery in Patients With Early-stage, Operable, Non-small Cell Lung Cancer
This Phase III study is testing whether adding durvalumab immunotherapy after chemotherapy and surgery helps patients with early-stage non-small cell lung cancer live longer without their disease returning. The study focuses on patients with operable lung cancer stages IIB to IIIB who have not fully responded to initial treatments. This could provide a new option to strengthen treatment success for these patients.
TrialsAlert subscribers received the full impact-classified briefing and doctor-ready report this week. Get weekly briefings at trialsalert.com.